AARTIDRUGS

- Board of Directors approved the "Aarti Drugs Limited Performance Stock Option Plan 2026" to grant up to 8,00,000 Performance Stock Options, convertible into equity shares of face value ₹10 each, subject to members' approval.

- Board Meeting scheduled for Thursday, August 27, 2026. - Agenda includes consideration and approval of the 'Aarti Drugs Limited – Performance Stock Option Plan 2026'. - Trading Window to remain closed from August 25, 2026, till August 29, 2026.

- Analyst / Institutional Investor Meetings Schedule - Meeting Date: 20th August 2026 - Meeting Time: 1:00 PM to 6:00 PM

- Aarti Drugs Limited won a legal dispute against the GST Department. - The Hon'ble Supreme Court dismissed the GST Department's Special Leave Petition regarding a demand for IGST and penalty of ₹20.72 Crores. - The ruling is in the company's favor with no financial or operational impact.

New Filing detected. See link for details.

- Concall Schedule - Concall Date: 10th August 2026 - Concall Time: 11:00 AM to 1:00 PM - Nature of Meeting: 1x1/ Group Meeting - Organised by: Nirmal Bang - Venue: Trident BKC, Mumbai

- Audio recording of the Investors/Analyst conference call on the Financial Results for the Quarter ended June 30, 2026, has been uploaded to the company's website. - The transcript for the call will be shared and uploaded in due course. - Link to recording: https://www.aartidrugs.com/reports-fillings-concall-recording

- Consolidated Revenue ₹703.6Cr vs ₹590.8Cr (▲19% YoY) - EBITDA ₹96.9Cr vs ₹74.4Cr (▲30% YoY) - PAT ₹50.1Cr vs ₹54.0Cr (▼7% YoY) - EBITDA Margin 13.8% vs 12.6% (▲120bps)

- Gujarat Pollution Control Board (GPCB) revoked the closure direction for Aarti Drugs' Sayakha plant, allowing continued Amines manufacturing. - An interim Environmental Damage Compensation of ₹10,20,000 was paid for past non-compliances. - The company states no financial or operational impact.

- Leadership transition announced by Aarti Drugs Limited effective October 1, 2026. - Shri Prakash M. Patil to retire as Chairman, Managing Director & CEO effective September 30, 2026, and will continue to provide guidance. - Shri Rashesh C. Gogri elevated to Chairman in addition to his existing role as Managing Director. - Shri Adhish P. Patil appointed as Managing Director (subject to shareholder approval). - The changes are aimed at strengthening governance and ensuring long-term strategic growth.

- Chairman, MD & CEO Shri Prakash M. Patil retires Sept 30, 2026 for orderly leadership transition. - Shri Rashesh C. Gogri elevated to Chairman (retains MD), and Shri Adhish P. Patil (CFO) appointed new MD, both effective Oct 1, 2026. - Shri Nilesh B. Patil appointed Whole-time Director; other directors re-appointed. - Board committees reconstituted to reflect changes.

- Consolidated Revenue ₹702.78 Cr vs ₹590.51 Cr (▲19.0% YoY) - EBITDA ₹96.11 Cr vs ₹74.08 Cr (▲29.7% YoY) - PAT ₹50.13 Cr vs ₹53.97 Cr (▼7.1% YoY) - EBITDA Margin 13.7% vs 12.5% (▲113bps)